BLOOD AND TISSUE BANKING IN GYNECOLOGICAL MALIGNANCIES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 妇科癌症是妇女癌症相关死亡的主要原因之一。 卵巢癌仍然是最致命的妇科恶性肿瘤。 每年约有26，500名女性被诊断患有卵巢癌，卵巢癌在女性癌症死亡率中排名第五。 卵巢癌患者的5年生存率仅为47%。 这些较差的生存统计数据部分是由于缺乏早期症状，导致在晚期疾病阶段进行诊断。 关于卵巢癌的发生和扩散的生物分子过程知之甚少，我们对其他妇科恶性肿瘤的了解也远未完成。 然而，公认的是，正常细胞增殖的改变，包括细胞生长增加和/或细胞死亡减少，导致组织稳态失衡，并有助于肿瘤生长的起始和进展。 临床标本和患者临床数据库将为确定根除卵巢癌和其他妇科癌症的新治疗和筛查方式提供宝贵的工具。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Gynecologic cancers are one of the main causes of cancer-related death in women. Ovarian cancer remains the most deadly gynecologic malignancy. Approximately 26,500 women are diagnosed with ovarian cancer each year and ovarian cancer is ranked fifth in cancer mortality among women. The overall 5 year survival rate of ovarian cancer patients is only 47%. These poor survival statistics are due in part to the lack of early symptoms which leads diagnosis at advanced disease stages. Little is known about he biomolecular processes governing the initiation and spread of ovarian cancer and our knowledge of other gynecologic malignancies is nowhere near complete. It is well accepted, however, that alterations in normal cell proliferation including increased cell growth and/or decreased cell death cause an imbalance in tissue homeostasis and contribute to the initiation and progression of tumor growth. The banking of clinical specimens and patient clinical data will provide an invaluable tool for identifying new therapeutic and screening modalities of the eradication of ovarian cancer and other gynecologic cancers.